Weekly ReportSep 7–13, 2026
Sepsis, week 37 edition
We read 197 papers and selected 3.
Summary
This week’s sepsis literature emphasized dynamic, precision-oriented approaches spanning molecular mechanisms, adaptive therapeutics, diagnosis, and risk stratification. Major advances included identification of AMBRA1 as an allosteric activator of the NLRP3 inflammasome, validation of macrophage-derived IL-39 as a prognostic and therapeutic target, and development of disease-stage-synchronized nanozyme therapy in preclinical polymicrobial sepsis. Clinical studies also supported serial physiological assessment, individualized fluid and antimicrobial management, procalcitonin-guided antibiotic de-escalation, and trajectory-based organ dysfunction phenotyping, while highlighting that many promising interventions still require prospective validation.
Selected Articles
1. AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition.
This mechanistic study identifies AMBRA1 as a scaffold and allosteric activator that releases NLRP3 from its closed, autorepressed conformation. AMBRA1 deficiency reduced NLRP3 activation and inflammatory responses in mouse models of endotoxic shock, colitis, and sepsis, while nanobody blockade of the AMBRA1-NLRP3 interaction inhibited inflammasome activation.
Impact: The study reveals a previously undefined upstream mechanism controlling NLRP3 activation and provides a structurally informed therapeutic entry point for sepsis and other inflammasome-mediated diseases.
Clinical Implications: The findings support development of selective inhibitors that disrupt the AMBRA1-NLRP3 interaction, but clinical translation requires validation in human sepsis, assessment of infection control, pharmacokinetics, and safety.
Key Findings
- AMBRA1 binds NLRP3 and destabilizes its closed autorepressed conformation, facilitating activation.
- Genetic deficiency or nanobody blockade of AMBRA1 reduced inflammatory responses in mouse models of endotoxic shock, colitis, and sepsis.
2. Interleukin-39 is a Prognostic Biomarker and Therapy Target for Sepsis.
Across two independent patient cohorts, circulating IL-39 was elevated at sepsis presentation and predicted 28-day survival. Single-cell and mouse experiments identified macrophage-derived IL-39 as a causal aggravator of sepsis through GP130-dependent MAPK/P38 signaling; genetic suppression or antibody neutralization was protective.
Impact: The study connects a measurable human biomarker with a cell-specific causal mechanism and therapeutic intervention, advancing IL-39 from an association to a candidate precision-treatment target.
Clinical Implications: IL-39 may eventually support admission risk stratification and biomarker-enriched trials of IL-39 or GP130 inhibition, but prospective validation and careful monitoring for impaired pathogen clearance are essential.
Key Findings
- Serum IL-39 was elevated in septic patients across two independent cohorts and predicted 28-day survival.
- Macrophage-specific IL-39 or GP130 manipulation demonstrated a causal role in sepsis severity through MAPK/P38 signaling.
3. Disease-Stage Synchronized Nanozyme Therapy for Polymicrobial Sepsis through Adaptive Catalytic and Immune Reprogramming.
The MICP@HG pH-adaptive nanozyme changed function during sepsis progression: it promoted antibacterial activity and cuproptosis-like bacterial killing in acidic infectious environments, then shifted toward antioxidant activity and reparative macrophage reprogramming as inflammation resolved. In polymicrobial sepsis models, the platform reduced inflammation, preserved organ function, improved survival, and generated trained immunity against reinfection.
Impact: This study addresses the time-varying biology of sepsis with a single platform that coordinates antibacterial, antioxidant, and immunomodulatory effects, representing a major conceptual advance beyond static therapies.
Clinical Implications: The platform offers a potential framework for treating polymicrobial and multidrug-resistant sepsis, but translation requires extensive studies of biodistribution, toxicity, pharmacokinetics, manufacturing, and large-animal efficacy.
Key Findings
- MICP@HG promoted antibacterial activity in acidic infectious microenvironments and shifted to antioxidant and anti-inflammatory functions as conditions normalized.
- The platform reduced systemic inflammation, protected organs, improved survival in polymicrobial sepsis models, and conferred protection against reinfection.